top of page
    • Jun 26

Intellia's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy

Laura Sepp-Lorenzino shares details of this news and offers her opinion of the significance of it, and provides an overview of Intellia's development plans for its ATTR amyloidosis and AATD programs.



Comments

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

Visit NYSE

bottom of page